Bank of America’s Kyverna Therapeutics KYTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$481K Buy
55,728
+27,019
+94% +$225K ﹤0.01% 4921
2025
Q4
$270K Sell
28,709
-36,255
-56% -$269K ﹤0.01% 5200
2025
Q3
$390K Buy
64,964
+31,208
+92% +$125K ﹤0.01% 5943
2025
Q2
$104K Buy
33,756
+16,430
+95% +$40.6K ﹤0.01% 6506
2025
Q1
$33.4K Sell
17,326
-4,462
-20% -$13.2K ﹤0.01% 6844
2024
Q4
$81.5K Buy
21,788
+6,400
+42% +$30.7K ﹤0.01% 6480
2024
Q3
$75.2K Sell
15,388
-9,811
-39% -$75.6K ﹤0.01% 6435
2024
Q2
$189K Buy
25,199
+12,183
+94% +$186K ﹤0.01% 5912
2024
Q1
$323K Buy
+13,016
New +$363K ﹤0.01% 5613

Other funds holding KYTX

Bank of America's KYTX Position: Q1 2026 in Review

Bank of America increased its Kyverna Therapeutics (KYTX) stake by 94% in Q1 2026, buying an estimated $225K and bringing the position to 55,728 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #4921.

Bank of America first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Bank of America held 55,728 shares of Kyverna Therapeutics worth $481K as of Q1 2026.
  • Bank of America bought 27,019 Kyverna Therapeutics shares in Q1 2026, an estimated $225K.
  • Kyverna Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4921 holding.
  • Bank of America first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.